World J Oncol
World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Original Article

Volume 2, Number 5, October 2011, pages 232-237


Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors

Julie Bienertova-Vaskua, c, d, Josef Tomandlb, Petr Bienerta, Josef Chovanecc, Zuzana Dostalovac, Anna Vaskua, Dalibor Valikc

aDepartment of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5 A18, Brno, Czech Republic
bDepartment of Biochemistry, Faculty of Medicine, Masaryk University, Kamenice 5 A16, Brno, Czech Republic
cMasaryk Memorial Cancer Institute, Brno, 602 00, Czech Republic
dCorresponding author: Julie Bienertova-Vasku, Email:

Manuscript accepted for publication October 6, 2011
Short title: Agouti-Related Peptide
doi: https://doi.org/10.4021/wjon385w

Abstract▴Top 

Background: Recently, it has been reported that central administration of agouti-related peptide (AgRP) might have protective effect against cachexia development in tumor-bearing mice. In this study, we determined whether the disease-free endometrial cancer survivors present with different plasma AgRP levels than controls and whether there was an association with the duration of the disease-free interval.

Methods: The total of 53 endometrial cancer survivors was enrolled in the study along with 93 healthy control women of similar age. Fasting blood samples were obtained and AgRP plasma levels determined using ELISA-based methodology.

Results: The AgRP plasma levels were significantly higher in the cases than in the controls; AgRP levels were the lowest in obese control women (77.4 ± 19.8 pg/ml); on the contrary, the AgRP plasma levels were highest in non-obese cancer survivors (100.5 ± 21.12 pg/ml). Moreover, we observed significant differences in AgRP levels between the endometrial cancer survivors and the control subjects [p (for comparison of the cases and the controls) = 0.002]. In the regression modeling, AgRP was significantly associated with the BMI as well as the case-control status, and the case-control differences in AgRP levels retained their statistical significance also after adjustment for BMI.

Conclusions: Disease-free endometrial cancer survivors who did not develop cachexia during their treatment as well as post-treatment period present with significantly higher AgRP levels than the control population, independently on their BMI and menopausal status which could be indicative of the protective effect of circulating AgRP against cachexia development in endometrial cancer.

Keywords: Agouti-related peptide; Cachexia; Cancer; Cancer survivors

Introduction▴Top 

Agouti related peptide (AgRP) is an endogenous antagonist of the anorexigenic neuropeptide melanocyte-stimulating hormone (MSH), derived from the proopiomelanocortin (POMC) molecule [1], that is capable of promoting food intake and positive energy balance through inhibition of the α-MSH-related signaling [2-4]. Moreover, inhibition of melanocortin signaling with AgRP or deletion of the specific receptor or treatment with melanocortin-4 receptor (MC-4R) antagonist in other experiments resulted in increased food intake and reduced energy expenditure [5-8].

The homeostasis of food intake and body weight is controlled by complex feedback loops, and even though their exact nature is largely uncertain, it is clear that hypothalamus plays a crucial role in integrating central and peripheral signaling. In the central nervous system, AgRP is produced exclusively by neurons in the arcuate nucleus (ARC) where it is co-expressed with neuropeptide Y (NPY) [9] and the inhibitory neurotransmitter γ-aminobutyric acid [10], whereas acute intracerebroventricular administration of AgRP [11] as well as overexpression of AgRP in transgenic animals [6] induce increase in body weight along with hyperphagia. This is well in accordance with the finding that the ARC is a key point integrating peripheral signals of energy balance, and regulating energy homeostasis by transmitting signals that modulate eating behavior and metabolism [12-15].

Cancer cachexia is characterized by preferential loss of adipose tissue; muscle mass is also affected [15], but wasting of muscle mass represents a common symptom of cachexia in some patients. Severe and progressive loss of fat-free mass involves both skeletal muscle and not visceral protein reserves and reflects decreases in both cellular mass and intracellular potassium concentration thus indicating severe impairment of energy metabolism [16], possibly mediated via TNF-alpha and the tumor factor proteolysis-inducing factor [17].

Loss of adipose tissue in cancer-related cachexia is secondary to a decrease in adipocyte lipid content and associates with changes in the expression of genes that regulate energy turnover, cytoskeleton and extracellular matrix, which suggests high tissue remodeling [18]. It has been proposed that changes in gene expression observed in cachexia are reciprocal to those observed in obesity [18], which implies the involvement of identical peripheral and central pathways.

Central administration of AgRP (83-132) into the lateral ventricles significantly increased body weight and food intake in tumor-bearing mice, and changes in muscle mass were similar to the tumor-free control mice [19], suggesting that AgRP may play a crucial role in regulation of energy balance in cancer-related cachexia.

The aim of the present study was to investigate differences in AgRP circulating levels between endometrial cancer survivors and healthy controls of similar age and gender distribution. We hypothesized that possible differences in circulating levels of AgRP between healthy controls subjects with various BMI and disease-free endometrial cancer survivors may exist as the cases 1) did not develop cancer cachexia; 2) mostly presented with abundant adipose tissue and 3) were obese and therefore could be expected to present with elevated leptin levels [20-21] that are inversely correlated with AgRP levels. Considering the previously reported negative correlation between AgRP plasma levels and leptin plasma levels [22], we expected the plasma AgRP levels to be negatively correlated with BMI in our study.

Material and Methods▴Top 

Subjects

Fifty three endometrial cancer patients (mean age 63.2 ± 10.5 y) were enrolled in the study at the Clinic of Obstetrics and Gynaecology of the Masaryk University Affiliated Hospital, Brno along with 93 control women of similar BMIs and the same ethnic (Central-European Caucasian) origin (mean age 47.1 ± 12.0 y). All cases in the study were postmenopausal (mean age 63.2 ± 10.5 y); the control group consisted of 45 premenopausal women (mean age 39.2 ± 7.3 y) and 48 post-menopausal patients (mean age 57.3 ± 6.4 y).

All of the endometrial cancer cases met the following criteria: (1) diagnosed with endometrial cancer that was either confined to the uterine corpus or extended only to the cervix (FIGO [International Federation of Gynecology and Obstetrics] stage I or II (stage I, n = 31; stage II, n = 22) or SEER [Surveillance Epidemiology and End Results] stage 1- 3), (2) received treatment at the Clinic of Obstetrics and Gynaecology of the Masaryk University Affiliated Hospital, (3) treated with surgery and/or radiation, (4) age 18 years or older, (4) disease-free for three or more years (mean duration of disease-free interval was 6.52 ± 4.58 y). The diagnosis of the cancer-related cachexia was based on the criteria set in the study by Strasser et al. [23], whereas a weight loss of ≥ 2% or ≥ 5% within 6 months before the study that was not related to recent surgery was considered the presence of cachexia. Based on these criteria, none of the cases in the study developed cancer-related cachexia, either during the oncological therapy or after it.

The control population was recruited from healthy individuals enrolled at the Department of Preventive Medicine of the Faculty of Medicine of the Masaryk University. The presence of malignancy or severe chronic diseases was excluded by a standardized complex physical examination and personal history evaluation. The measurement of height was performed with a calibrated stadiometer and weight (in light indoor clothes and without shoes) was measured with a calibrated set of scales. The study was approved by the Committee for Ethics of Medical Experiments on Human Subjects, Faculty of Medicine, Masaryk University, Brno, and performed in adherence to the Declaration of Helsinki Guidelines. Each participant gave her written informed consent that has been archived.

Biochemical analysis

Venous blood samples were collected into tripotassium EDTA-tubes after overnight fasting and immediately centrifuged at 1700 ≥ g for 20 min and then stored at -80 °C until analysis. AgRP plasma levels were measured using a commercially available ELISA kit (Quantikine, R&D Systems, Minneapolis, MN, USA) according to the instructions of the manufacturer.

Statistics

Where applicable, it was first determined whether the variable presented a normal distribution using the Kolmogorov-Smirnov test, and in cases of skewed variables, logarithmic transformation was performed. For descriptive purposes, mean values are presented using untransformed values. Results are expressed as mean values and standard deviations unless otherwise stated.

In the next step, we performed Pearson’s correlation testing between AgRP and clinical as well as anthropometric parameters and we report the Pearson’s r coefficients, giving the strength of an association in the range of -1 and +1.

To identify variables that may contribute to predicting the anthropometric or clinical phenotype, we carried out a conditional logistic regression. Generally, conditional logistic regression models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for the associations between plasma AgRP levels and endometrial cancer risk. Fisher’s exact test with Tukey-Kramer’s method of adjustment for multiple comparisons was employed for comparison of categorical variables. The data analysis was performed using the Statistica v. 8.0 (Statsoft Inc., Tulsa, OK, USA) program package. The conventional values of p ≤ 0.05 were considered statistically significant.

Results▴Top 

The baseline characteristics of the study subjects are summarized in Table 1. Overall, the mean plasma AgRP concentration was 14% higher for cases, compared to the control subjects (p = 0.002). The AgRP plasma levels were lower in non-obese control women (88.1 ± 24.4 pg/ml), and they reached their minimum in obese control women (77.4 ± 19.8 pg/ml); on the contrary, AgRP plasma level was the highest in non-obese endometrial cancer survivors (100.5 ± 21.12 pg/ml) and slightly lower in obese endometrial cancer survivors (91.5 ± 33.1 pg/ml); the differences in AgRP between investigated groups were statistically significant [p (for comparison of the cases and the controls) = 0.002]. The mean AgRP plasma concentrations remained consistently higher among cases, compared with the controls, when stratified by menopausal status, BMI or smoking status, although the differences were not always statistically significant. In a separate analysis of AgRP plasma levels according to parity, no significant associations were observed either in the cases or the controls (Table 2). No association of AgRP plasma levels with age was observed (r = -0.015, p = 0.858).

Table 1.
Click to view
Table 1. Baseline Characteristics of the Study Subjects
 

Table 2.
Click to view
Table 2. Plasma AgRP Values According to the Parity
 

AgRP plasma levels and obesity

Pearson partial correlation coefficients, adjusted for age and case-control status (i.e. in analysis performed across the pooled survivors and control subjects), showed that plasma AgRP levels were significantly negatively correlated with investigated measures of adiposity. Conditional logistic regression analyses revealed a strong association between AgRP concentration and case-control status (β = -0.22, p = 0.006), independently on BMI of the subjects.

When performing the univariate regression tests across the whole studied cohort (pooled cases and the controls), AgRP expressed correlation with BMI (β = -0.22, p = 0.006). This observed relationship retained its statistical significance also after adjustment for age and smoking status (β = -0.22, p = 0.006), whereas the non-obese females presented with higher levels of AgRP (92.4 ± 23.9 pg/ml) than the obese women (82.7 ± 26.3 pg/ml; p = 0.009).

AgRP plasma levels according to menopausal status

AgRP plasma levels in premenopausal control women (83.8 ± 24.1 pg/ml) and postmenopausal control women (79.4 ± 20.2 pg/ml) tended to be lower than in the cases that were all postmenopausal (94.7 ± 29.5 pg/ml; respectively, p = 0.40), however, these results did not achieve statistical significance. No association of AgRP plasma levels with age at menarche or age at menopause in the controls was observed; the cases were excluded from this analysis as menopause in some of the cases resulted artificially from the treatment of the disease.

Discussion▴Top 

In the presented study, we investigated plasma AgRP levels in a sample of 53 endometrial cancer survivors and compared them to 93 controls of similar age, BMI and various menopausal status. We demonstrated significant differences in AgRP plasma levels between obese and non-obese endometrial cancer survivors as well as across the whole cohort of endometrial cancer survivors and the controls, whereas this association was age-independent. Moreover, we observed a significant association of AgRP levels previous history of endometrial cancer, independently on BMI and age, indicating that endometrial cancer survivors could present with habitually elevated AgRP levels compared to the control population that could protect them against cachexia development.

Physiological plasma levels of AgRP show significant variation during life, the average plasma levels reported for the adolescent girls with BMI are 30.1 ± 16.9 pg/ml [24], while Katsuka et al. [25] report significant differences in AgRP levels between the obese (14.46 ± 2.5 pg/ml) and nonobese women (6.0 ± 0.5 pg/ml, p < 0.05), hence on a very small population sample. In another study, reported plasma levels of AgRP were 49.4 ± 2.4 pg/ml in the obese individuals compared to 10.1 ± 0.9 pg/ ml in the lean subjects and there was a significant correlation with the fat mass (P < 0.001), percentage body fat (P < 0.001) and leptin (P < 0.05) [22]. The AgRP levels observed in our were almost 2-times higher in our study, but it has to be mentioned that the study by Hoggard et al. was conducted on a very small set of male volunteers and no large population study is available so far to estimate gender-related effects of AgRP. Recently, it has been reported by our research group that plasma levels of AgRP express extreme variation both in maternal serum and umbilical cord blood in the peripartum period [26], which is indicative of AgRP plasma levels showing substantial variations during life. The differences in AgRP levels between the presented study and other published papers could be also explained by the effect of age as our study subjects were significantly older. The other possible explanation could be that the observed higher AgRP levels were associated with higher BMI of our study subjects, which is also consistent with our finding of significant correlation of BMI and AgRP circulating levels.

Our pilot results showed that AgRP plasma levels differ between endometrial cancer survivors and healthy population; although this correlation was BMI-dependent, it retained the statistical significance after adjustment for BMI; the non-obese women with long-term disease-free survival of endometrial cancer presented with highest AgRP levels, while the lowest AgRP levels were observed in obese healthy women.

It has been known for a long time that successful removal of the tumor can be associated with the cachexia reversal process and significant changes in various metabolic pathways were observed after tumor excision in experimental animals [27-28]. It has to be noted, however, that the patient selected for our study were completely disease-free for at least three years, so we did not expect any significant effect of tumor removal on the actual AgRP levels in these subjects and we presume that the increased AgRP levels are rather a constitutive trait or a function of BMI than a reaction to tumor removal.

The exact nature of the regulatory feedback circuits involving AgRP, regulating feeding and satiety behavior remains unclear. The previous reports on AgRP plasma levels in relation to BMI are highly controversial. It has been reported that plasma levels of AgRP were elevated in anorexia nervosa [29], while plasma alpha-MSH levels were not significantly different in this study. On the other hand, elevated levels of AgRP were observed in a cohort of obese men, where the AgRP levels were correlated with the plasma levels of alpha-MSH, independently from the total fat area [25]. In our study, we observed increased AgRP levels in non-obese subjects, independently on their case-control status. The inverse relationship between AgRP and BMI could be explained by previously reported inverse relationship between AgRP plasma levels and plasma leptin levels [22]. Indeed, plasma AgRP levels were experimentally suppressed by peripheral leptin administration in fasted humans [24].

As we observed a strong trend towards the increased AgRP levels in endometrial-cancer survivors, which remained significant also after adjustment for BMI, we hypothesized that apart from possible relationship of AgRP levels and BMI, reflecting roughly the fat “reserves”, there may be another underlying mechanism making the cancer survivors in our study less prone to develop cancer cachexia than others. It is possible that the increased circulating AgRP levels might stimulate feeding behavior and inhibit pro-cachechtic pathways, thus making our cancer survivors less prone to cachexia-related complications. Our observation is well in accordance with the findings on animal models by Markison et al. [30-31] reporting that central application of exogenous AgRP (83-132) or systemic MC4R antagonists can protect against the anorexic effect of LLC (Lewis lung carcinoma) tumors.

Taken together, our data suggest that AgRP may play a role in preventing cancer-related cachexia development, which supports the hypothesis of possible clinical utility of AgRP agonists. However, further studies focused on potential therapeutic potential of AgRP agonists on substantially larger population samples with different ethnicity and age structure, possibly with prospective design, are a necessity.

Acknowledgments

Each author has made an important scientific contribution to the study and has assisted with the drafting or revising of the manuscript, in accordance with the definition of an author as stated by the International Committee of Medical Journal Editors.The present study was supported by the projects MZMOU2005 and RECAMO CZ.1.05/2.1.00/03.0101. The authors are grateful to Jolana Lipkova and Marian Hlavna for technical assistance in ELISA analyses.


References▴Top 
  1. Coll AP, Loraine Tung YC. Pro-opiomelanocortin (POMC)-derived peptides and the regulation of energy homeostasis. Mol Cell Endocrinol. 2009;300(1-2):147-151.
    pubmed doi
  2. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997;278(5335):135-138.
    pubmed doi
  3. Stutz AM, Morrison CD, Argyropoulos G. The agouti-related protein and its role in energy homeostasis. Peptides. 2005;26(10):1771-1781.
    pubmed doi
  4. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571-578.
    pubmed doi
  5. Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van Der Ploeg LH, Woods SC, et al. Long-term orexigenic effects of AgRP-(83---132) involve mechanisms other than melanocortin receptor blockade. Am J Physiol Regul Integr Comp Physiol. 2000;279(1):R47-52.
    pubmed
  6. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KL. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet. 1997;17(3):273-274.
    pubmed doi
  7. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, Stark KL. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 1997;11(5):593-602.
    pubmed doi
  8. Mizuno TM, Mobbs CV. Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. Endocrinology. 1999;140(2):814-817.
    pubmed doi
  9. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci. 1998;1(4):271-272.
    pubmed doi
  10. Backberg M, Collin M, Ovesjo ML, Meister B. Chemical coding of GABA(B) receptor-immunoreactive neurones in hypothalamic regions regulating body weight. J Neuroendocrinol. 2003;15(1):1-14.
    pubmed doi
  11. Goto K, Inui A, Takimoto Y, Yuzuriha H, Asakawa A, Kawamura Y, Tsuji H, et al. Acute intracerebroventricular administration of either carboxyl-terminal or amino-terminal fragments of agouti-related peptide produces a long-term decrease in energy expenditure in rats. Int J Mol Med. 2003;12(3):379-383.
    pubmed
  12. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411(6836):480-484.
    pubmed doi
  13. Jovanovic Z, Tung YC, Lam BY, O'Rahilly S, Yeo GS. Identification of the global transcriptomic response of the hypothalamic arcuate nucleus to fasting and leptin. J Neuroendocrinol. 2010;22(8):915-925.
    pubmed
  14. Jovanovic Z, Yeo GS. Central leptin signalling: beyond the arcuate nucleus. Auton Neurosci. 2010;156(1-2):8-14.
    pubmed doi
  15. Gordon JN, Green SR, Goggin PM. Cancer cachexia. QJM. 2005;98(11):779-788.
    pubmed doi
  16. Topkan E, Yavuz AA, Ozyilkan O. Cancer cachexia: pathophysiologic aspects and treatment options. Asian Pac J Cancer Prev. 2007;8(3):445-451.
    pubmed
  17. Tisdale MJ. Are tumoral factors responsible for host tissue wasting in cancer cachexia?. Future Oncol. 2010;6(4):503-513.
    pubmed doi
  18. Dahlman I, Mejhert N, Linder K, Agustsson T, Mutch DM, Kulyte A, Isaksson B, et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer. 2010;102(10):1541-1548.
    pubmed doi
  19. Joppa MA, Gogas KR, Foster AC, Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides. 2007;28(3):636-642.
    pubmed doi
  20. Tessitore L, Vizio B, Pesola D, Cecchini F, Mussa A, Argiles JM, Benedetto C. Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol. 2004;24(6):1529-1535.
    pubmed
  21. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, Trichopoulos D. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab. 2002;46(3-4):147-151.
    pubmed doi
  22. Hoggard N, Johnstone AM, Faber P, Gibney ER, Elia M, Lobley G, Rayner V, et al. Plasma concentrations of alpha-MSH, AgRP and leptin in lean and obese men and their relationship to differing states of energy balance perturbation. Clin Endocrinol (Oxf). 2004;61(1):31-39.
    pubmed doi
  23. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschop M, Kaufmann K, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008;98(2):300-308.
    pubmed doi
  24. Gavrila A, Chan JL, Miller LC, Heist K, Yiannakouris N, Mantzoros CS. Circulating melanin-concentrating hormone, agouti-related protein, and alpha-melanocyte-stimulating hormone levels in relation to body composition: alterations in response to food deprivation and recombinant human leptin administration. J Clin Endocrinol Metab. 2005;90(2):1047-1054.
    pubmed doi
  25. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Tanaka T, Furuta M, Araki-Sasaki R, et al. Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metab. 2001;86(5):1921-1924.
    pubmed doi
  26. Bienertova-Vasku J, Bienert P, Tomandl J, Lipkova J, Zlamal F, Dostalova Z, Vasku A. Comparison of agouti-related peptide levels in peripheral blood of postpartum pre-eclamptic and non pre-eclamptic women and in umbilical cord blood from their pregnancies. Diabetes Res Clin Pract. 2010;89(3):e53-55.
    pubmed doi
  27. Younes RN, Vydelingum NA, Noguchi Y, Brennan MF. Lipid kinetic alterations in tumor-bearing rats: reversal by tumor excision. J Surg Res. 1990;48(4):324-328.
    pubmed doi
  28. Le Bricon T, Cynober L, Baracos VE. Protein metabolism in cachectic tumor-bearing rats: effect of tumor excision. J Surg Res. 1996;60(1):207-215.
    pubmed doi
  29. Moriya J, Takimoto Y, Yoshiuchi K, Shimosawa T, Akabayashi A. Plasma agouti-related protein levels in women with anorexia nervosa. Psychoneuroendocrinology. 2006;31(9):1057-1061.
    pubmed doi
  30. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SR, Fleck BA, et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology. 2005;146(6):2766-2773.
    pubmed doi
  31. Chen C, Tucci FC, Jiang W, Tran JA, Fleck BA, Hoare SR, Wen J, et al. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem. 2008;16(10):5606-5618.
    pubmed


This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


World Journal of Oncology is published by Elmer Press Inc.

 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

World Journal of Oncology, bimonthly, ISSN 1920-4531 (print), 1920-454X (online), published by Elmer Press Inc.        
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.wjon.org   editorial contact: editor@wjon.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!